Conference overview19 Mar 2026 14:20
Dr. Vladislav Sandler, the CEO of Hemogenyx Pharmaceuticals, presented today, March 19, 2026, at the H.C. Wainwright Global Investment Conference.
The talk served as a strategic update for investors and clinical partners, focusing on the company’s transition from a pre-clinical to a clinical-stage biotech firm.
Key Highlights of the Talk
HG-CT-1 Progress: Vlad provided a significant update on the HEMO-CAR-T program. He confirmed that the Phase I clinical trial for relapsed/refractory Acute Myeloid Leukemia (AML) is advancing well, specifically mentioning the move into higher dose cohorts following positive safety data from initial patients.
Pediatric Expansion: A major point of the talk was the inclusion of pediatric patients. Following recent regulatory clearances, the trial is now recruiting patients aged 12–18, which significantly expands the potential impact of their CAR-T therapy.
The CBR Platform: He detailed the Chimeric Bait Receptor (CBR) platform, describing it as a "next-generation" immunotherapy. Unlike traditional CAR-T, this platform aims to reprogram innate immune cells to fight not only cancers but also viral infections, positioning Hemogenyx within the biodefense sector.
Near-Term Revenue Strategy: Vlad discussed the company’s unique approach to early commercialization, specifically mentioning the Estonian hospital exemption law. This pathway could allow the company to generate revenue from their CAR-T therapy via government reimbursement before full global regulatory approval is finalized.
Manufacturing Partnerships: He highlighted recent technology transfers and partnerships designed to scale up "one-day manufacturing," which aims to reduce the time and cost of delivering cell therapies to patients.
Note: Dr. Sandler emphasized that these developments aim to make bone marrow transplantation—traditionally a "last resort" treatment—safer and more accessible for patients with blood and autoimmune diseases.